Medicis Pharmaceutical Corporation
10
0
0
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 15/100
0.0%
0 terminated/withdrawn out of 10 trials
100.0%
+13.5% vs industry average
70%
7 trials in Phase 3/4
60%
6 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Treatment of Forehead/Glabellar Rhytide Complex With Combination Botulinum Toxin A and Hyaluronic Acid Versus Botulinum Toxin A Injection Alone
Role: collaborator
Adherence to Study Medication Compared to Generic Topical Clindamycin Plus Generic Topical Tretinoin in Subjects With Mild to Moderate Acne Vulgaris
Role: collaborator
Efficacy of Fluocinonide Cream 0.1% (Vanos(R)) in Reducing Itch in Subjects With Atopic Dermatitis
Role: collaborator
A Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis
Role: collaborator
VANOS Cream and Skin Barrier Function
Role: collaborator
Onabotulinum Toxin Type A and Abobotulinum Toxin Type A Crow's Feet Rhytid Study
Role: collaborator
Brow Lifting With Dysport
Role: collaborator
Upper Facial Remodeling With Perlane-L and Dysport
Role: collaborator
Safety and Efficacy Study of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel to Treat Rosacea
Role: collaborator
A Study to Examine the Effects of Minocycline Extended-Release Tablets on Sperm Production in Human Males.
Role: lead
All 10 trials loaded